ZA200502738B - Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation - Google Patents
Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation Download PDFInfo
- Publication number
- ZA200502738B ZA200502738B ZA200502738A ZA200502738A ZA200502738B ZA 200502738 B ZA200502738 B ZA 200502738B ZA 200502738 A ZA200502738 A ZA 200502738A ZA 200502738 A ZA200502738 A ZA 200502738A ZA 200502738 B ZA200502738 B ZA 200502738B
- Authority
- ZA
- South Africa
- Prior art keywords
- substituted
- alkyl
- group
- heteroaryl
- compound
- Prior art date
Links
- 230000004663 cell proliferation Effects 0.000 title claims description 10
- 230000002401 inhibitory effect Effects 0.000 title claims description 6
- BVNWQSXXRMNYKH-UHFFFAOYSA-N 4-phenyl-2h-benzotriazole Chemical class C1=CC=CC=C1C1=CC=CC2=C1NN=N2 BVNWQSXXRMNYKH-UHFFFAOYSA-N 0.000 title description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 150
- 125000000217 alkyl group Chemical group 0.000 claims description 97
- 125000001624 naphthyl group Chemical group 0.000 claims description 83
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 83
- 229910052739 hydrogen Inorganic materials 0.000 claims description 76
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 66
- 125000005842 heteroatom Chemical group 0.000 claims description 66
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 64
- 150000001875 compounds Chemical class 0.000 claims description 59
- 125000001931 aliphatic group Chemical group 0.000 claims description 53
- 125000003367 polycyclic group Chemical group 0.000 claims description 52
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 49
- 229910052757 nitrogen Inorganic materials 0.000 claims description 39
- 229910052736 halogen Inorganic materials 0.000 claims description 34
- 150000002367 halogens Chemical class 0.000 claims description 34
- 229910052760 oxygen Inorganic materials 0.000 claims description 34
- 125000001424 substituent group Chemical group 0.000 claims description 34
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 33
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 33
- 239000001301 oxygen Substances 0.000 claims description 33
- 229910052717 sulfur Inorganic materials 0.000 claims description 33
- 239000011593 sulfur Substances 0.000 claims description 33
- 125000003545 alkoxy group Chemical group 0.000 claims description 31
- 208000006673 asthma Diseases 0.000 claims description 28
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 17
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims description 16
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 16
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 16
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 16
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 16
- 125000003282 alkyl amino group Chemical group 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 239000003112 inhibitor Substances 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 14
- 125000003107 substituted aryl group Chemical group 0.000 claims description 14
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 11
- 206010020751 Hypersensitivity Diseases 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 5
- 102000004127 Cytokines Human genes 0.000 claims description 5
- 239000000048 adrenergic agonist Substances 0.000 claims description 5
- 210000000265 leukocyte Anatomy 0.000 claims description 5
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 239000003246 corticosteroid Substances 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 239000000812 cholinergic antagonist Substances 0.000 claims description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 30
- UYJXRRSPUVSSMN-UHFFFAOYSA-P ammonium sulfide Chemical compound [NH4+].[NH4+].[S-2] UYJXRRSPUVSSMN-UHFFFAOYSA-P 0.000 claims 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 6
- 239000004615 ingredient Substances 0.000 claims 6
- 150000001263 acyl chlorides Chemical class 0.000 claims 5
- 208000030961 allergic reaction Diseases 0.000 claims 4
- -1 camphoryl Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical class C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims 1
- 150000003920 1,2,4-triazines Chemical class 0.000 claims 1
- 150000000182 1,3,5-triazines Chemical class 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 229940111121 antirheumatic drug quinolines Drugs 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 150000008371 chromenes Chemical class 0.000 claims 1
- 150000001907 coumarones Chemical class 0.000 claims 1
- ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical group C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 150000002240 furans Chemical class 0.000 claims 1
- 150000002460 imidazoles Chemical class 0.000 claims 1
- 150000002475 indoles Chemical class 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 150000002537 isoquinolines Chemical class 0.000 claims 1
- 150000003854 isothiazoles Chemical class 0.000 claims 1
- 150000002545 isoxazoles Chemical class 0.000 claims 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 claims 1
- 150000002916 oxazoles Chemical class 0.000 claims 1
- 150000004880 oxines Chemical class 0.000 claims 1
- 150000003216 pyrazines Chemical class 0.000 claims 1
- 150000003217 pyrazoles Chemical class 0.000 claims 1
- 150000004892 pyridazines Chemical class 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 150000003233 pyrroles Chemical class 0.000 claims 1
- 150000003248 quinolines Chemical class 0.000 claims 1
- 150000003557 thiazoles Chemical class 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 150000003577 thiophenes Chemical class 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 description 13
- 229940079593 drug Drugs 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000007815 allergy Effects 0.000 description 6
- 208000026935 allergic disease Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 230000036427 bronchial hyperreactivity Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 206010006482 Bronchospasm Diseases 0.000 description 3
- 230000007885 bronchoconstriction Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical class C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960000265 cromoglicic acid Drugs 0.000 description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 229960004398 nedocromil Drugs 0.000 description 2
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229940020697 accolate Drugs 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004574 azelastine Drugs 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000021953 cytokinesis Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 208000010485 smooth muscle tumor Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960004764 zafirlukast Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41076102P | 2002-09-12 | 2002-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200502738B true ZA200502738B (en) | 2007-04-25 |
Family
ID=31994198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200502738A ZA200502738B (en) | 2002-09-12 | 2005-04-05 | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7256287B2 (OSRAM) |
| EP (1) | EP1546157A4 (OSRAM) |
| JP (1) | JP2006503048A (OSRAM) |
| KR (1) | KR20050050102A (OSRAM) |
| CN (1) | CN1694889A (OSRAM) |
| AR (1) | AR041252A1 (OSRAM) |
| AU (1) | AU2003279729A1 (OSRAM) |
| BR (1) | BR0314235A (OSRAM) |
| CA (1) | CA2498495A1 (OSRAM) |
| MX (1) | MXJL05000010A (OSRAM) |
| NZ (1) | NZ538547A (OSRAM) |
| PE (1) | PE20050036A1 (OSRAM) |
| PL (1) | PL375811A1 (OSRAM) |
| RU (1) | RU2005109911A (OSRAM) |
| TW (1) | TWI276631B (OSRAM) |
| WO (1) | WO2004024897A2 (OSRAM) |
| ZA (1) | ZA200502738B (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6919366B2 (en) * | 1998-05-22 | 2005-07-19 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
| US6911462B2 (en) * | 1998-05-22 | 2005-06-28 | Avanir Pharmaceuticals | Benzimidazole compounds for regulating IgE |
| PT1368028E (pt) * | 2001-03-12 | 2007-11-26 | Avanir Pharmaceuticals | Compostos de benzimidazole para modulação de ige e inibição da proliferação celular |
| TW200304820A (en) * | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| WO2005013950A2 (en) * | 2003-08-08 | 2005-02-17 | Avanir Pharmaceuticals | Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| WO2005056547A2 (en) | 2003-12-04 | 2005-06-23 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
| DE502005002697D1 (de) | 2004-10-13 | 2008-03-13 | Merck Patent Gmbh | Als kinaseinhibitoren geeignete derivate des n,n'-diphenylharnstoffs |
| US7786113B2 (en) | 2004-12-23 | 2010-08-31 | Hoffman-La Roche Inc. | Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents |
| EP1833829A2 (en) * | 2004-12-23 | 2007-09-19 | F. Hoffmann-Roche AG | Benzamide substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors |
| KR20060087386A (ko) | 2005-01-28 | 2006-08-02 | 주식회사 대웅제약 | 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물 |
| CN101208339B (zh) * | 2005-08-01 | 2010-12-29 | 霍夫曼-拉罗奇有限公司 | 杂环苄基氨基衍生物，它们的制备以及作为药剂的应用 |
| CN101511828A (zh) | 2006-09-06 | 2009-08-19 | 霍夫曼-拉罗奇有限公司 | 作为蛋白激酶抑制剂的杂芳基衍生物 |
| MX2010009410A (es) | 2008-02-29 | 2010-11-30 | Array Biopharma Inc | Compuestos del inhibidor de raf y métodos de uso de los mismos. |
| CA2895905A1 (en) | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
| GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| WO2014151729A1 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
| WO2014151630A2 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| WO2015004533A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| PL3010503T3 (pl) | 2013-06-21 | 2020-08-24 | Zenith Epigenetics Ltd. | Nowe bicykliczne inhibitory bromodomen |
| EP3027604B1 (en) | 2013-07-31 | 2019-02-20 | Zenith Epigenetics Ltd. | Novel quinazolinones as bromodomain inhibitors |
| TWI674263B (zh) | 2013-12-19 | 2019-10-11 | 瑞士商諾華公司 | 用於治療寄生蟲疾病之化合物及組合物 |
| CN103819398B (zh) * | 2014-01-24 | 2016-05-04 | 河北科技大学 | 4-氨基-2-氯-3-硝基吡啶的合成方法 |
| WO2016034673A1 (en) | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Tetrahydroisoquinoline derived prmt5-inhibitors |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| US10005792B2 (en) | 2014-09-03 | 2018-06-26 | Ctxt Pty. Ltd. | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors |
| EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
| CN107207474B (zh) | 2014-12-11 | 2021-05-07 | 恒翼生物医药科技(上海)有限公司 | 被取代的杂环作为溴结构域抑制剂 |
| US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
| WO2017103670A1 (en) * | 2015-12-14 | 2017-06-22 | Zenith Epigenetics Lid. | 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors |
| GB201604031D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604030D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604029D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604022D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604020D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| GB201604027D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
| US11548867B2 (en) | 2017-07-19 | 2023-01-10 | Idea Ya Biosciences, Inc. | Amido compounds as AhR modulators |
| JP7588224B2 (ja) | 2020-10-05 | 2024-11-21 | エンライブン インコーポレイテッド | Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物 |
| US20220127231A1 (en) * | 2020-10-27 | 2022-04-28 | Shilpa Medicare Ltd | Process for the prepartion of amifampridine phosphate |
| KR102818206B1 (ko) * | 2021-07-12 | 2025-06-11 | 한양대학교 에리카산학협력단 | 인다졸일 벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3985891A (en) | 1973-02-03 | 1976-10-12 | Boehringer Ingelheim Gmbh | 2-Phenyl-imidazo (4,5-b)pyridines and salts thereof |
| DE3224512A1 (de) | 1982-07-01 | 1984-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue imidazolderivate, ihre herstellung und diese verbindungen enthaltende arzneimittel |
| US4510158A (en) | 1984-03-05 | 1985-04-09 | Sterling Drug Inc. | 2-Phenylindole derivatives, their use as complement inhibitors |
| AU591495B2 (en) | 1985-05-03 | 1989-12-07 | Foxboro Company, The | Distillation cut point control |
| US4939133A (en) | 1985-10-01 | 1990-07-03 | Warner-Lambert Company | N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade |
| LU86258A1 (fr) | 1986-01-21 | 1987-09-03 | Rech Dermatologiques C I R D S | Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique |
| US5206257A (en) | 1987-03-05 | 1993-04-27 | May & Baker Limited | Pesticidal method using 2-phenylimidazole derivatives |
| JP2630432B2 (ja) | 1987-08-24 | 1997-07-16 | コニカ株式会社 | 新規なシアンカプラーを含有するハロゲン化銀カラー写真感光材料 |
| KR900700132A (ko) | 1988-02-02 | 1990-08-11 | 에릭 에스. 딕커 | 면역 글로불린 e 반응 억제 방법 |
| JP2700475B2 (ja) | 1988-07-30 | 1998-01-21 | コニカ株式会社 | 非線形光学材料および非線形光学素子 |
| IT1232252B (it) | 1989-02-22 | 1992-01-28 | Rotta Research Lab | Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione |
| FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
| EP0415886A3 (en) | 1989-08-30 | 1991-10-23 | Ciba-Geigy Ag | Aza compounds |
| FR2658511B1 (fr) | 1990-02-16 | 1992-06-19 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant. |
| WO1992002500A1 (fr) | 1990-07-31 | 1992-02-20 | Teikoku Hormone Mfg. Co., Ltd. | Derive de 2-phenylindole |
| DE69113162T2 (de) | 1990-08-02 | 1996-03-14 | Hoffmann La Roche | Antiallergische Mischung. |
| US5646281A (en) | 1990-12-28 | 1997-07-08 | Neurogen Corporation | Certain 4-piperidino- and piperazinomethyl-2-phenyl imidazole derivatives; dopamine receptor subtype specific ligands |
| JPH06263993A (ja) | 1991-01-21 | 1994-09-20 | Konica Corp | アゾメチン系染料、インドアニリン系染料及びインドフェノール系染料の製造法 |
| IE71647B1 (en) | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
| ES2102036T3 (es) | 1992-06-15 | 1997-07-16 | Celltech Therapeutics Ltd | Derivados con grupo fenilo trisustituido utilizados como inhibidores selectivos de la fosfodiesterasa iv. |
| US5733740A (en) * | 1992-10-13 | 1998-03-31 | Vanderbilt University | Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma |
| US5322847A (en) | 1992-11-05 | 1994-06-21 | Pfizer Inc. | Azabenzimidazoles in the treatment of asthma, arthritis and related diseases |
| EP0694535A1 (en) | 1994-04-29 | 1996-01-31 | Eli Lilly And Company | Non-peptidyl tachykinin receptor antagonists |
| US5643893A (en) | 1994-06-22 | 1997-07-01 | Macronex, Inc. | N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines |
| DE4426625A1 (de) | 1994-07-27 | 1996-03-14 | Schering Ag | 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US5496826A (en) | 1994-09-02 | 1996-03-05 | Bristol-Myers Squibb Company | Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides |
| US5821258A (en) | 1994-12-27 | 1998-10-13 | Mitsui Chemicals, Inc. | Phenylbenzimidazole derivatives |
| DE19503160A1 (de) | 1995-02-01 | 1996-08-08 | Bayer Ag | Verwendung von Phenylcyclohexylcarbonsäureamiden |
| JPH11510154A (ja) | 1995-08-02 | 1999-09-07 | ニューキャッスル ユニバーシティ ベンチャーズ リミテッド | ベンズイミダゾール化合物 |
| US6387938B1 (en) | 1996-07-05 | 2002-05-14 | Mochida Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| TW467902B (en) | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| US6153631A (en) | 1996-10-23 | 2000-11-28 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
| AU4988997A (en) | 1996-10-23 | 1998-05-15 | Osteoscreen, Inc. | Compositions and methods for treating bone deficit conditions |
| CA2232467A1 (en) | 1997-03-20 | 1998-09-20 | Richard A. Glennon | Imidazoles with serotonin receptor binding activity |
| US6034256A (en) | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| DK0994890T3 (da) | 1997-06-10 | 2003-12-01 | Univ Michigan | Benzimidazolderivater |
| GB9718833D0 (en) | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
| UA72448C2 (en) | 1997-09-26 | 2005-03-15 | Zentaris Gmbh | Azabenzimidazole-based compounds, methods for their synthesis and pharmaceutical composition, method for modulating function of serine/threonine protein kinases with azabenzimidazole-based compounds, method for identifying compounds modulating functioning of serine/threonine protein kinase, method for preventing and treating serine/threonine protein kinase-related abnormal conditions with azabenzimidazole-based compounds |
| US6100282A (en) | 1998-01-02 | 2000-08-08 | Hoffman-La Roche Inc. | Thiazole derivatives |
| US6911462B2 (en) | 1998-05-22 | 2005-06-28 | Avanir Pharmaceuticals | Benzimidazole compounds for regulating IgE |
| US6369091B1 (en) | 1998-05-22 | 2002-04-09 | Avanir Pharmaceuticals | Benzimidazole analogs as down-regulators of IgE |
| US6919366B2 (en) | 1998-05-22 | 2005-07-19 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
| US6303645B1 (en) | 1998-05-22 | 2001-10-16 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
| HUP0102128A3 (en) | 1998-05-22 | 2002-05-28 | Avanir Pharmaceuticals San Die | Mediciaments containing benzimidazole derivatives as modulators of ige |
| JP2000095767A (ja) | 1998-09-28 | 2000-04-04 | Takeda Chem Ind Ltd | 性腺刺激ホルモン放出ホルモン拮抗剤 |
| DE59911249D1 (de) | 1998-11-03 | 2005-01-13 | Abbott Gmbh & Co Kg | Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung |
| RU2001116581A (ru) | 1998-11-17 | 2004-02-20 | БАСФ Акциенгезельшафт (DE) | Замещенные 2-фенилбензимидазолы и 2-фенилиндолы, их получение и применение |
| RU2001117757A (ru) | 1998-11-27 | 2004-02-27 | БАСФ Акциенгезельшафт (DE) | Замещенные бензимидазолы и их применение в качестве ингибиторов поли(аденозиндифосфатрибоза)полимеразы |
| DE19918211A1 (de) | 1999-04-22 | 2000-10-26 | Basf Ag | Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung |
| DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| US6423734B1 (en) | 1999-08-13 | 2002-07-23 | The Procter & Gamble Company | Method of preventing cancer |
| DE19939463A1 (de) | 1999-08-20 | 2001-02-22 | Boehringer Ingelheim Pharma | Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US6759425B2 (en) | 1999-10-21 | 2004-07-06 | Avanir Pharmaceuticals | Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| US6242461B1 (en) | 2000-01-25 | 2001-06-05 | Pfizer Inc. | Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases |
| GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
| WO2002072574A1 (en) | 2001-03-12 | 2002-09-19 | Janssen Pharmaceutica N.V. | Process for the preparation of imidazole compounds |
| PT1368028E (pt) | 2001-03-12 | 2007-11-26 | Avanir Pharmaceuticals | Compostos de benzimidazole para modulação de ige e inibição da proliferação celular |
| US6777442B2 (en) | 2001-03-12 | 2004-08-17 | Bayer Aktiengesellschaft | Diphenyl derivatives |
| NZ530580A (en) * | 2001-07-27 | 2007-02-23 | Curis Inc | Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| TW200304820A (en) | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| US20040229927A1 (en) | 2003-04-10 | 2004-11-18 | Sircar Jagadish C. | Imidazole derivatives for treatment of allergic and hyperproliferative disorders |
| WO2005013950A2 (en) | 2003-08-08 | 2005-02-17 | Avanir Pharmaceuticals | Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
-
2003
- 2003-09-10 TW TW092124975A patent/TWI276631B/zh not_active IP Right Cessation
- 2003-09-12 MX MXJL05000010A patent/MXJL05000010A/es not_active Application Discontinuation
- 2003-09-12 PE PE2003000933A patent/PE20050036A1/es not_active Application Discontinuation
- 2003-09-12 CA CA002498495A patent/CA2498495A1/en not_active Abandoned
- 2003-09-12 US US10/661,296 patent/US7256287B2/en not_active Expired - Fee Related
- 2003-09-12 NZ NZ538547A patent/NZ538547A/en unknown
- 2003-09-12 WO PCT/US2003/030962 patent/WO2004024897A2/en not_active Ceased
- 2003-09-12 AR ARP030103321A patent/AR041252A1/es not_active Application Discontinuation
- 2003-09-12 KR KR1020057004331A patent/KR20050050102A/ko not_active Withdrawn
- 2003-09-12 EP EP03773067A patent/EP1546157A4/en not_active Withdrawn
- 2003-09-12 CN CNA038250934A patent/CN1694889A/zh active Pending
- 2003-09-12 BR BR0314235-3A patent/BR0314235A/pt not_active IP Right Cessation
- 2003-09-12 AU AU2003279729A patent/AU2003279729A1/en not_active Abandoned
- 2003-09-12 PL PL03375811A patent/PL375811A1/xx not_active Application Discontinuation
- 2003-09-12 JP JP2004536644A patent/JP2006503048A/ja not_active Withdrawn
- 2003-09-12 RU RU2005109911/04A patent/RU2005109911A/ru not_active Application Discontinuation
-
2005
- 2005-04-05 ZA ZA200502738A patent/ZA200502738B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20050036A1 (es) | 2005-01-24 |
| AR041252A1 (es) | 2005-05-11 |
| EP1546157A4 (en) | 2007-02-28 |
| CA2498495A1 (en) | 2004-03-25 |
| KR20050050102A (ko) | 2005-05-27 |
| US20040116466A1 (en) | 2004-06-17 |
| WO2004024897A3 (en) | 2004-08-26 |
| NZ538547A (en) | 2007-05-31 |
| JP2006503048A (ja) | 2006-01-26 |
| CN1694889A (zh) | 2005-11-09 |
| TWI276631B (en) | 2007-03-21 |
| PL375811A1 (en) | 2005-12-12 |
| MXJL05000010A (es) | 2005-06-07 |
| US7256287B2 (en) | 2007-08-14 |
| WO2004024897A2 (en) | 2004-03-25 |
| AU2003279729A1 (en) | 2004-04-30 |
| TW200404784A (en) | 2004-04-01 |
| BR0314235A (pt) | 2005-08-09 |
| RU2005109911A (ru) | 2006-04-27 |
| EP1546157A2 (en) | 2005-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200502738B (en) | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation | |
| ZA200007752B (en) | Compounds having IgE affecting properties. | |
| JP6391071B2 (ja) | シスタチオニン−γ−リアーゼ（ＣＳＥ）阻害剤 | |
| ZA200508108B (en) | Imidazole derivatives for treatment of allergic and hyperproliferative disorders | |
| ZA200502739B (en) | Phenyl-indole compounds. | |
| Awadzi | Clinical picture and outcome of serious adverse events in the treatment of onchocerciasis | |
| US20220047594A1 (en) | Method for treating interstitial lung disease | |
| AU2022208237A9 (en) | 4-chloro-n-[2-[(4-chlorophenyl)methyl]-3-oxo-1,2,4-thiadiazol-5-yl]benzamide for use in medicine | |
| WO2017125523A1 (en) | Treatment of hand eczema | |
| TW201521727A (zh) | 使用巴比妥酸鹽衍生物來降低尿酸位準的方法 | |
| EP4157290A1 (en) | Compositions, their uses in therapy and methods thereof | |
| CN105358148A (zh) | 用于治疗肾小球疾病的losmapimod | |
| WO1997024333A1 (en) | Preventives/remedies for complications of diabetes | |
| WO2011091461A1 (de) | Verbindungen zur verwendung bei der behandlung von erkrankungen | |
| US4952594A (en) | Reagents and method for therapeutic treatment of multiple sclerosis | |
| JP3142559B2 (ja) | 止痒剤としての血小板活性化因子拮抗剤の用途 | |
| EP1363634A2 (en) | Compounds for the treatment of addictive disorders | |
| CN110279691B (zh) | 一种外科术后护理镇痛药物及其用途 | |
| WO2017139497A1 (en) | Hedgehog inhibitor for use in relief of and treatment of pruritus or itching | |
| JPS5835186A (ja) | ジカルボキシアミノチアゾール誘導体およびそれを含有する免疫調節組成物 | |
| RU2313341C1 (ru) | Средство, обладающее местно-анестезирующим действием | |
| CN103251627B (zh) | 甘珀酸或其盐在制备治疗炎症性疾病的药物中的应用 | |
| US20060111356A1 (en) | External preparation for allergic diseases | |
| WO2004016590A1 (en) | The salts of the quinuclidine derivatives and the preparation and applications thereof | |
| CN119896660A (zh) | 酰胺衍生物在制备治疗或预防皮肤辐射损伤药物上的应用 |